The International Association for the Study of Lung Cancer Staging Project: The Impact of Common Molecular Alterations on Overall Survival in NSCLC in Initial Analyses of the IASLC Ninth Edition Staging Database
Journal of Thoracic Oncology · 2025-10 · 20 (10) · 1423-1440
DOI: 10.1016/j.jtho.2025.06.025 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Thoracic Oncology, 2025-10. Verfasst von David P Carbone und 22 weiteren Autor:innen. Beteiligte Einrichtung: Ohio State James Thoracic Oncology Center and Pelotonia Institute for Immune Oncology, Columbus, Ohio. Electronic address: David.carbone@osumc.edu. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: NCI NIH HHS, AstraZeneca, International Association for the Study of Lung Cancer.
Abstract (Originalsprache)
INTRODUCTION: TNM staging systems create prognostic categories by anatomic extent of disease. Whether therapeutically important molecular alterations in NSCLC augment the prognostic information of TNM staging is unclear. To study this, we analyzed molecular data from the ninth edition of the lung cancer staging system. METHODS: Eligible patients were diagnosed between 2011 and 2019. Analysis was restricted to the following three genes for reliable statistical analyses: EGFR mutations (L858R, exon 19 deletion), ALK fusions, and KRAS mutations (codons 12, 13, or 61). Overall survival (OS) was calculated by the Kaplan-Meier method, and differences in OS were assessed by Cox proportional hazard regression models. RESULTS: A total of 20,580 patients had tumors with molecular data (EGFR = 16,497, ALK = 11,546, KRAS = 2909 patients). EGFR mutations were found in 5428 (32.9%), ALK fusions in 723 (6.3%), and KRAS mutations in 890 (30.6%) tumors. OS was significantly better across all TNM stages among patients with EGFR-mutated tumors and patients with stage IV ALK fusion-positive tumors, whereas patients with stage I KRAS-mutated tumors had significantly worse OS. Multivariable analyses confirmed the OS associations with EGFR-mutated tumors (stage I hazard ratio [HR] = 0.79, stage II HR = 0.71, stage III HR = 0.67, stage IV HR = 0.49) and stage IV ALK fusion-positive tumors (HR = 0.56). CONCLUSIONS: Patients with EGFR-mutated tumors had improved OS regardless of stage, whereas an OS benefit was found in stage IV patients with ALK-positive tumors. In the tenth edition, we will evaluate the systematic integration of molecular biomarkers and treatment to refine prognostication for molecular subsets of NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Ohio State James Thoracic Oncology Center and Pelotonia Institute for Immune Oncology, Columbus, Ohio. Electronic address: David.carbone@osumc.edu.
- Center for Thoracic Oncology/Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
- Multidisciplinary Thoracic Oncology Program, Baptist Cancer Center, Memphis, Tennessee.
- Cancer Research And Biostatistics, Seattle, Washington.
- Princess Margaret Cancer Centre and University of Toronto, Toronto, Ontario, Canada.
- Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Förderung
- NCI NIH HHS
- AstraZeneca
- International Association for the Study of Lung Cancer
Zitieren
APA
Carbone, D. P., Hirsch, F. R., Osarogiagbon, R. U., Nishimura, K. K., Tsao, M. S., Travis, W. D., Yang, D., Yang, S. R., Yatabe, Y., Araujo, L. H., Detterbeck, F., Lechtenberg, K. J., Lim, E., Mack, P. C., Matilla, J. M., Montuenga, L. M., Nicholson, A. G., Suda, K., Terra, R. M., …, & Members of the IASLC Staging and Prognostic Factors Committee and of the Advisory Boards, and Participating Institutions (2025). The International Association for the Study of Lung Cancer Staging Project: The Impact of Common Molecular Alterations on Overall Survival in NSCLC in Initial Analyses of the IASLC Ninth Edition Staging Database. Journal of Thoracic Oncology, 20(10), 1423-1440. https://doi.org/10.1016/j.jtho.2025.06.025
Vancouver
Carbone DP, Hirsch FR, Osarogiagbon RU, Nishimura KK, Tsao MS, Travis WD, et al. The International Association for the Study of Lung Cancer Staging Project: The Impact of Common Molecular Alterations on Overall Survival in NSCLC in Initial Analyses of the IASLC Ninth Edition Staging Database. Journal of Thoracic Oncology. 2025;20(10):1423-1440. doi:10.1016/j.jtho.2025.06.025
BibTeX
@article{Carbone2025,
author = {Carbone, David P and Hirsch, Fred R and Osarogiagbon, Raymond Uyiosa and Nishimura, Katherine K and Tsao, Ming Sound and Travis, William D and Yang, Dawei and Yang, Soo-Ryum and Yatabe, Yasushi and Araujo, Luiz Henrique and Detterbeck, Frank and Lechtenberg, Kendra J and Lim, Eric and Mack, Philip C and Matilla, José-María and Montuenga, Luis M and Nicholson, Andrew G and Suda, Kenichi and Terra, Ricardo M and Rami-Porta, Ramón and Asamura, Hisao and Rusch, Valerie and Members of the IASLC Staging and Prognostic Factors Committee and of the Advisory Boards, and Participating Institutions, Members of the IASLC Staging and Prognostic Factors Committee and of the Advisory Boards, and Participating Institutions},
title = {The International Association for the Study of Lung Cancer Staging Project: The Impact of Common Molecular Alterations on Overall Survival in NSCLC in Initial Analyses of the IASLC Ninth Edition Staging Database},
journal = {Journal of Thoracic Oncology},
year = {2025},
volume = {20},
number = {10},
pages = {1423--1440},
doi = {10.1016/j.jtho.2025.06.025}
}
EUVIMED